Bevacizumab for Retinopathy of Prematurity

To the Editor: The study by Mintz-Hittner et al. (Feb. 17 issue) 1 advances our knowledge about the use of bevacizumab for the treatment of retinopathy of prematurity, but important questions remain about this drug's safety and efficacy. In the absence of functional vision testing or patient safety data, the sweeping endorsement of an experimental new treatment is unwarranted. Lack of protection against investigator bias is a concern. Assessment of the primary outcome (i.e., recurrence of retinopathy of prematurity requiring retreatment) by two ophthalmologists who were aware of the treatment assignments leaves the door open for such bias to influence results. . . .